Imaging lymph vessels in rheumatoid arthritis before and during treatment
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This Phase 1 study uses special imaging to look at lymph vessels in people with rheumatoid arthritis (RA). The goal is to better understand changes in the lymph system in early versus long-standing RA and during certain treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and able to sign consent papers
- You must have RA that fits the study’s definitions of early (≤1 year) or established (at least 10 years)
- Your RA symptoms must be active, including hand joint inflammation confirmed by an ultrasound
- For early RA, you should be on methotrexate (MTX) and not responding enough, or have a flare on MTX and be starting an anti-TNF medicine
- For established RA, you must be on a stable RA medicine for at least 8 weeks (such as MTX, leflunomide, sulfasalazine, hydroxychloroquine, a JAK inhibitor, or a biologic)
- You cannot be allergic to iodine (because the study uses a dye that contains iodide)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special “light tracer” medicine with adalimumab to see where inflammation is in the gut (IBD) or joints (RA). If you have active disease, it may help doctors better target treatment by showing inflammation more clearly during scans.
This study tests whether a special scan can help doctors decide if you can safely reduce your rheumatoid arthritis medication. It may help you taper your treatment while keeping your disease under control.
This study tests if a lung ultrasound can detect early signs of lung disease in people with rheumatoid arthritis. It may help you if you have certain risk factors, like being male, older, or a smoker.
This trial tests how a radioactive imaging medicine (a tracer called 68Ga-DOTA-Siglec-9) spreads in the body and how well it shows inflammation. It includes both healthy volunteers and people with active rheumatoid arthritis, vasculitis, or pulmonary sarcoidosis to see if the scan matches disease activity.
This study uses a laser-based imaging method to “see” inflammation in people with rheumatoid arthritis. It may help researchers better understand how active joint inflammation looks and how it changes.
This trial uses a special PET scan to see how an experimental drug, CIT-013, targets inflammation in the body. It's for people with rheumatoid arthritis to better understand how the drug works.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.